Table 3. Associations of NLR, dNLR, PLR and LMR with other clinicopathological factors.
| Factor | NLR, Median(IQR) | P | d-NLR, Median(IQR) | P | PLR, Median(IQR) | P | LMR, Median(IQR) | P |
|---|---|---|---|---|---|---|---|---|
| Total | 3.07(2.20–4.78) | 2.11(1.65–3.02) | 122(85–183) | 3.32(2.12–4.53) | ||||
| Age (years) | 0.928 | 0.789 | 0.265 | 0.986 | ||||
| ≤60 | 3.12(2.21–4.89) | 2.11(1.64–3.27) | 132(87–199) | 3.34(2.10–4.52) | ||||
| >60 | 3.01(2.19–4.51) | 2.13(1.70–2.69) | 100(81–167) | 3.27(2.61–4.72) | ||||
| Gender | 0.480 | 0.044 | 0.875 | 0.853 | ||||
| Male | 2.96(2.15–4.78) | 2.03(1.59–2.57) | 130(85–179) | 3.38(2.00–4.53) | ||||
| Female | 3.21(2.51–4.72) | 2.33(1.84–3.34) | 122(84–203) | 3.23(2.44–4.68) | ||||
| Presentation | 0.105 | 0.041 | 0.208 | 0.430 | ||||
| Incidental | 2.94(1.96–4.39) | 1.98(1.50–2.59) | 121(72–180) | 3.39(2.15–4.63) | ||||
| Symptomatic | 3.17(2.51–4.96) | 2.27(1.73–3.18) | 138(94–192) | 3.20(2.06–4.50) | ||||
| Tumor site | 0.531 | 0.892 | 0.963 | 0.577 | ||||
| Left | 2.99(2.46–4.80) | 2.03(1.67–2.91) | 126(84–177) | 3.18(2.10–4.50) | ||||
| Right | 3.16(1.98–4.64) | 2.26(1.51–3.18) | 122(79–197) | 3.42(2.14–4.55) | ||||
| Tumor size (cm) | 0.014 | 0.013 | 0.004 | 0.014 | ||||
| ≤7 | 2.84(1.98–4.34) | 2.03(1.52–2.53) | 100(68–177) | 3.54(2.66–4.86) | ||||
| >7 | 3.52(2.51–5.30) | 2.29(1.80–3.54) | 153(155–224) | 2.83(2.00–3.65) | ||||
| T stage | 0.283 | 0.174 | 0.302 | 0.930 | ||||
| T1 + T2 | 2.85(2.21–4.45) | 1.98(1.65–2.73) | 121(77–185) | 3.26(2.11–4.73) | ||||
| T3 + T4 | 3.35(2.18–5.39) | 2.48(1.67–3.27) | 142(93–188) | 3.39(2.41–4.12) | ||||
| N stage | 0.701 | 0.471 | 0.214 | 0.739 | ||||
| N0 | 3.07(2.19–4.51) | 2.12(1.63–2.70) | 122(82–175) | 3.35(2.11–4.72) | ||||
| N1 | 3.06(2.35–5.16) | 2.13(1.70–3.29) | 153(85–238) | 3.21(2.23–4.21) | ||||
| M stage | 0.245 | 0.254 | 0.062 | 0.044 | ||||
| M0 | 2.94(2.17–4.51) | 1.98(1.64–2.70) | 121(75–169) | 3.43(2.24–4.76) | ||||
| M1 | 3.92(2.34–4.91) | 2.18(1.76–3.27) | 155(97–222) | 2.74(2.04–3.54) | ||||
| TNM stage | 0.022 | 0.044 | 0.001 | 0.006 | ||||
| I | 2.64(1.91–3.38) | 1.71(1.50–2.38) | 87(57–137) | 3.88(2.76–5.03) | ||||
| II | 3.52(2.78–5.44) | 2.26(1.77–3.26) | 143(121–206) | 2.49(1.81–3.42) | ||||
| III | 3.17(2.20–5.66) | 2.33(1.68–3.37) | 122(85–192) | 3.54(2.75–4.53) | ||||
| IV | 3.92(2.34–4.91) | 2.18(1.76–3.27) | 155(97–222) | 2.74(2.04–3.54) | ||||
| Histology | 0.034 | 0.379 | 0.007 | 0.010 | ||||
| Clear Cell | 2.86(2.15–4.74) | 2.12(1.59–3.02) | 121(73–167) | 3.42(2.64–4.72) | ||||
| Non–clear Cell | 3.65(2.80–5.41) | 2.12(1.95–3.05) | 179(106–247) | 2.21(1.84–3.23) | ||||
| Tumor necrosis | 0.049 | 0.028 | 0.058 | 0.025 | ||||
| Absent | 2.85(2.03–4.11) | 1.85(1.54–2.38) | 115(69–178) | 3.59(2.52–4.87) | ||||
| Present | 3.43(2.51–4.98) | 2.31(1.71–3.27) | 139(95–216) | 3.10(2.11–3.69) | ||||
| Microvascular invasion | 0.167 | 0.297 | 0.013 | 0.089 | ||||
| Absent | 2.91(2.18–4.57) | 2.04(1.65–2.91) | 120(73–180) | 3.36(2.46–4.73) | ||||
| Present | 3.51(2.61–6.12) | 2.48(1.72–3.26) | 163(121–226) | 2.74(1.71–3.80) | ||||
| Percentage sarcomatoid (%) | 0.771 | 0.552 | 0.710 | 0.561 | ||||
| <50 | 3.01(2.36–4.33) | 2.11(1.66–2.69) | 130(93–183) | 3.35(2.00–4.07) | ||||
| ≥50 | 3.25(2.05–5.40) | 2.16(1.60–3.35) | 122(70–190) | 3.23(2.25–4.68) |
IQR = interquartile range; NLR = neutrophil count to lymphocyte count; dNLR = neutrophil count to (white cell count – neutrophil count); PLR = platelet count to lymphocyte count; LMR = lymphocyte to monocyte ratio.